Hyperuricemia
Conditions
Keywords
Febuxostat, Efficacy, Safety, Allopurinol, Hyperuricemia, Zurig, Getz Pharma
Brief summary
Febuxostat is a potent, nonpurine, selective inhibitor of Xanthine oxidase that exhibits antihyperuricemic activity by reducing the formation of uric acid. The investigators conducted an interventional, two-arm, randomized, open label pilot study on patients with serum urate level ≥ 6.8 mg/dL. Patients were treated with Febuxostat 40 mg Tablets or Allopurinol 300 mg Tablets once daily dose for 90 days to determine the efficacy and safety of Febuxostat in comparison with Allopurinol in Hyperuricemic Subjects with or without Gout.
Detailed description
Patients with hyperuricemia (with or without Gout) were randomized into two groups. One was treated with Febuxostat 40 mg Tablets and other with Allopurinol 300 mg Tablets once daily for 3 months period. Gender, age, height, weight, creatinine and ALT levels, co-morbidities and other complications were monitored at screening and as per eligibility criteria 50 patients were enrolled in the study. Efficacy was determined by monitoring serum uric acid levels during and at the end of treatment. The safety profile has also been monitored during the treatment period. Investigator collected and recorded all the data of visits in CRF which was analyzed through SPSS version 20.
Interventions
DRUGFebuxostat
Comparison of two anti-hyperuricemic molecules
DRUGAllopurinol
Comparison of two anti-hyperuricemic molecules
Sponsors
Getz Pharma
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Both genders from 18 to 75 years of age 2. Must have a serum urate level ≥ 6.8 milligram per deciliter (mg/dL) and/or subjects recruited with Gout; must meet American College of Rheumatology criteria for Gout. 3. Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study. 4. Patient willingly provides written informed consent
Exclusion criteria
1. History of significant concomitant illness 2. Active liver disease (SGPT\> 1.5 times the upper limit of normal range) 3. Severe renal impairment (Serum Creatinine level \>2mg/dl) 4. Any other significant medical condition that would interfere with the treatment, safety or compliance with the protocol, as defined by the investigator 5. Cardiac disease or stroke (current or previous history) 6. Has a known history of infection with hepatitis B, hepatitis C, or HIV 7. Has a history of cancer within 5 years prior to the first dose of study medication 8. Has a known hypersensitivity to febuxostat or allopurinol or any components of their formulation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum uric acid levels | 3 months | To determine the efficacy of Febuxostat once daily with Allopurinol once daily in hyperuricemic subjects for 3 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety Assessment: number of participant with adverse events | At week 2, week 4 and week 12 | To determine the number of patients treated with Febuxostat once daily with Allopurinol once daily who experience any adverse drug reaction. All ADR are reported as per patient information leaflet |
Countries
Pakistan
Outcome results
None listed